Teacher Retirement System of Texas Sells 10,124 Shares of Moderna, Inc. (NASDAQ:MRNA)

Teacher Retirement System of Texas decreased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 11.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 75,700 shares of the company's stock after selling 10,124 shares during the quarter. Teacher Retirement System of Texas' holdings in Moderna were worth $7,528,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its holdings in Moderna by 6,528.9% during the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company's stock worth $38,552,000 after purchasing an additional 381,808 shares during the last quarter. abrdn plc boosted its stake in shares of Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company's stock worth $48,091,000 after buying an additional 399,843 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Moderna by 19.2% in the fourth quarter. Van ECK Associates Corp now owns 270,774 shares of the company's stock valued at $26,929,000 after acquiring an additional 43,646 shares in the last quarter. Invesco Ltd. increased its position in shares of Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock valued at $322,887,000 after acquiring an additional 517,683 shares during the last quarter. Finally, First Trust Direct Indexing L.P. bought a new stake in Moderna during the fourth quarter worth $372,000. Institutional investors own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Canaccord Genuity Group upped their price objective on Moderna from $91.00 to $106.00 and gave the company a "hold" rating in a research note on Friday, May 3rd. UBS Group raised their price objective on shares of Moderna from $143.00 to $151.00 and gave the stock a "buy" rating in a report on Tuesday, May 7th. Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Oppenheimer raised their price target on shares of Moderna from $142.00 to $163.00 and gave the stock an "outperform" rating in a research note on Friday, May 3rd. Finally, Evercore ISI started coverage on Moderna in a research note on Tuesday. They issued an "in-line" rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $126.46.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $121.68, for a total value of $1,825,200.00. Following the transaction, the director now directly owns 2,011,931 shares in the company, valued at $244,811,764.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the completion of the sale, the insider now owns 8,557 shares of the company's stock, valued at $809,235.49. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company's stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $121.68, for a total value of $1,825,200.00. Following the completion of the transaction, the director now owns 2,011,931 shares of the company's stock, valued at $244,811,764.08. The disclosure for this sale can be found here. Insiders sold a total of 155,209 shares of company stock worth $16,678,621 over the last ninety days. 15.70% of the stock is owned by corporate insiders.

Moderna Price Performance

Shares of MRNA stock traded up $2.65 during trading hours on Tuesday, reaching $128.32. The stock had a trading volume of 3,621,998 shares, compared to its average volume of 4,098,155. The stock's fifty day simple moving average is $108.24 and its 200 day simple moving average is $96.29. The firm has a market capitalization of $49.18 billion, a PE ratio of -8.19 and a beta of 1.57. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business's quarterly revenue was down 91.0% compared to the same quarter last year. During the same period last year, the firm earned $0.19 EPS. On average, equities research analysts predict that Moderna, Inc. will post -7.53 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.